Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data

Executive Summary

CHICAGO – Merck showed dramatic HDL and LDL cholesterol effects and no safety concerns in the Phase III DEFINE study of anacetrapib, but it is still planning to wait to submit the cholesteryl ester transfer protein (CETP) inhibitor until the conclusion of a major outcomes trial.
Advertisement

Related Content

Merck Calls It Quits On Anacetrapib
Merck Calls It Quits On Anacetrapib
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
Out Of The Ashes: Roche’s Dalcetrapib Data Suggest Still Hope For CETP Inhibitor Class
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
Merck Taking Aggressive Approach To Cardiovascular Development
Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS052856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel